Google
RPRX — ROYALTY PHARMA PLC (Healthcare >> Biotechnology)
RPRX FAQ
What is RPRX's P/E ratio?
ROYALTY PHARMA PLC (RPRX) currently trades at a P/E ratio of 38.28.
What is RPRX's ROE?
ROYALTY PHARMA PLC reports a Return on Equity (ROE) of 12.01%.
What is RPRX's dividend yield?
ROYALTY PHARMA PLC offers a dividend yield of 1.63%.
What is RPRX's Deepscope Quality Score?
Deepscope rates RPRX's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RPRX?
Deepscope's AI Timing Score for RPRX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RPRX belong to?
ROYALTY PHARMA PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 55.87
Price
0.85
(1.54%)
Day Change
|
|
|---|
RPRX, the overall quality is very good ( Quality = 85) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROE is relatively low.
ROA is too relatively low compare to ROE
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...
| Quality Factors |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
2399
|
| Magic Formula Rank by ROE |
2399
|
| Magic Formula Rank by ROIC |
2503
|
| Price | 55.87 |
| PBV / Sector |
3.19 / 4.63
|
| Earning Per Share | 1.46 |
| PE / Sector |
38.28 / 17.43
|
| PEG or PE/Growth / Sector |
0.05 / 0.53
GREAT
|
| Average 1M Daily Value |
223.04 M
GREAT
|
| Average 1W Daily Value |
211.39 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
47% |
| Ability to Make Profit |
|
77% |
| Return to Investors |
|
12% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:01 |
| Symbol | RPRX |
| Name | ROYALTY PHARMA PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 443.27 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 31,682.29 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 110 East 59th Street, New York, NY, United States, 10022
Phone: 212 883 0200
Website: https://www.royaltypharma.com
Employees: 100
Sector: Healthcare >> Biotechnology
Description: Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
